This compares favorably with ORRs of 35–55% noted in phase 1/2 and 3 studies with quizartinib57,76 and gilteritinib58,77, in patients with relapsed/refractory FLT3-mutated AML – even though the patients in these trials were generally more favorable, with only 4–11% of patients exposed to prior tyrosine kinase inhibitor-based therapy. Here, FLT3 is linked to acute myeloid leukemia.